Fresenius Should Benefit From German Healthcare Reform -- Market Talk
Fresenius: Helios' Revenue Growth, 10%-12% EBIT Margin Targets Remain Unchanged
Fresenius: Approved Act Is More Favorable Than Cabinet Draf on Balance
Fresenius: Approved Act Preserves Annual Hospital Reimbursement Growth
Fresenius Says 2026 Guidance Unchanged After German Lawmakers Approve Healthcare Reform
Fresenius: Shareholders Approve All AGM Resolutions
Fresenius SE 公佈非GAAP每股收益爲€0.82,收入爲€57.4億;重申2026財年展望。
Fresenius Posts Higher Revenue, Earnings on Growth Across Units
Analysts Saw Fresenius 1Q Revenue Before Special Items at EUR5.82B
Analysts Saw Fresenius 1Q Before Special Items at EUR681.4M
Fresenius Says 1Q Performance Fully in Line With Expectations
Fresenius 1Q Revenue Before Special Items EUR5.74B, With Organic Growth of 5%
Fresenius 1Q Core Net Profit EUR460M
Fresenius 1Q EBIT Before Special Items EUR678M
Fresenius Backs 2026 View
FRESENIUS SE&CO KGAA SPON ADR EA REP 0.25 ORD SHS(FSNUY.US)將於05月06日發佈業績
$FRESENIUS SE&CO KGAA SPON ADR EA REP 0.25 ORD SHS(FSNUY.US)$將於05月06日發佈業績,投資者敬請關注。此前業績如何?$FRESENIUS SE&CO KGAA SPON ADR EA REP 0.25 ORD SHS(FSNUY.US)$2025Q4營業收入59.61億歐元,淨利潤3.61億歐元,每股收益0.158歐元。2025Q1營業
DaVita位居榜首,成爲唯一一家被評爲強力買入的大型醫療保健服務公司。
Fresenius SE Co. KGaA 報告了年度財務業績。
Fresenius Renews CEO's Contract as Net Profit Jumps
Fresenius 4Q Net Pft EUR361M